Answers are grounded in this paper and cite their sources.
Background The success of mRNA-lipid nanoparticle (LNP) platforms has prompted significant interest in their application against bacterial pathogens. However, adapting these platforms requires optimising host-expressed antigen structure to ensure robust immunogenicity. While membrane anchoring enhances the efficacy of viral mRNA vaccines, its application in bacterial mRNA platforms remains largely unexplored. Plague, caused by the Gram-negative bacterium Yersinia pestis , has been one of the most devastating diseases throughout human history. Despite extensive studies, there are no licenced vaccines available. Methods We developed a bivalent mRNA-LNP vaccine against Y. pestis , utilising the major antigens F1 and LcrV (5 μg of each mRNA). We evaluated glycosylphosphatidylinositol (GPI)-anchored and transmembrane (TM) variants alongside secreted native and hFc-conjugated formats to assess immunological profiles and determine protective efficacy in a murine model of pneumonic plague. Findings Membrane-tethering of F1 and LcrV antigens improved overall immunogenicity. Whereas secreted native and hFc-conjugated variants elicited predominantly cell-mediated and serological immune responses, respectively, the membrane-anchored bivalent mRNA vaccine generated a robust, protective immune response. This dual humoural and cellular immunity facilitated robust (87.5%, 7/8 mice) protection following a single-dose vaccination. Interpretation By progressing towards the single-dose biodefense benchmark prioritised by the World Health Organisation Target Product Profile, this membrane-anchored construct emerges as a promising translational candidate for a rapid-response plague vaccine. Ultimately, this study demonstrates that extending established antigen-tethering strategies to bacterial targets may be a highly effective approach for generating the potent immunity required to overcome complex bacterial infections. Funding This research was supported by the Israeli Science Foundation (grants 2012/20, 842/25), the Lewis Trust and the Shmunis Family Trust.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: